PER-096-03已完成未知
RANDOMIZED DOUBLE-BLIND STUDY, PHASE III TO COMPARE TWO ALBENDAZOLE SCHEMES FOR THE TREATMENT OF RACEMOSA CISTICERCOSIS
IVERSIDAD PERUANA CAYETANO HEREDIA,0 个研究点目标入组 0 人开始时间: 2004年1月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •- Male or female individuals between 18-65 year of age with a diagnosed of basal subarachnoid cysticercosis (including locations in the Sylvian fissure) by neuroimaging and confirmed by serology.
- •- Willingness to accomplish the two weeks minimal hospitalization required.
排除标准
- •- Previous therapy with albendazole or praziquantel.
- •- Pulmonary tuberculosis.
- •- Systemic disease other than neurocysticercosis that may affect therapy or short-term prognosis, including but not limited to chronic renal failurc, hepatic insufficiency, cardiac failure, and steroid-depcndent immune diseases.
- •- Patients in unstable condition or with severe intracranial hypertension (ICH).
- •- Pregnancy
研究者
相似试验
进行中（未招募）
1 期
The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The Sponsor of the study wants to prove that the new medication is not inferior regarding efficacy and safety as compared to the already approved medication LinezolidVentilated Gram-positive nosocomial pneumoniaMedDRA version: 17.0 Level: LLT Classification code 10052596 Term: Nosocomial pneumonia System Organ Class: 100000004862EUCTR2013-004154-22-GBTrius Therapeutics, a Wholly Owned Subsidiary of Cubist726
进行中（未招募）
1 期
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Subjects with Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)EUCTR2015-003376-75-BGAbbVie Deutschland GmbH & Co. KG600
进行中（未招募）
1 期
A Study to Compare Upadacitinib (ABT-494) to Placebo in Subjects with Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-BEYOND)EUCTR2015-003335-35-FIAbbVie Deutschland GmbH & Co. KG450
进行中（未招募）
1 期
A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT)EUCTR2015-003332-13-LTAbbVie Deutschland GmbH & Co. KG661
进行中（未招募）
1 期
A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(ies) (KEEPsAKE 2)Psoriatic arthritisEUCTR2017-002464-40-GBAbbVie Deutschland GmbH & Co. KG420